Which company produces osimertinib?

Osimertinib (Tagrisso), this revolutionary anti-cancer drug, is developed and produced by the British company AstraZeneca. AstraZeneca, as the world's leading biopharmaceutical company, has been committed to the research and development of innovative drugs to provide safer and more effective treatment options for patients around the world. The development of osimertinib is an important breakthrough for AstraZeneca in the field of anti-cancer.

Osimertinib, also known as Tagrisso, has attracted much attention in the domestic market. It is a third-generation EGFR tyrosine kinase inhibitor mainly used to treat advanced non-small cell lung cancer (NSCLC). It is particularly worth mentioning that osimertinib has a significant effect on NSCLC patients with EGFR mutations, especially those who have developed resistance after treatment with first- or second-generation EGFR inhibitors. Its common specifications are 30 tablets per box and 80 mg per tablet, which is also the standard dosage for patients during treatment.

Compared with traditional EGFR inhibitors, osimertinib has higher selectivity and stronger inhibitory effect. It can target specific gene mutations, such as the T790M mutation, and exert excellent therapeutic effects. Because of this, osimertinib has been widely recognized and used worldwide.

In addition to its excellent efficacy, osimertinib is also relatively convenient to administer. It is not affected by food and can be taken with or without food. Of course, like other anti-cancer drugs, osimertinib may also cause some side effects, such as skin rash, nail discoloration, and diarrhea. But overall, these side effects are controllable and well tolerated by most patients.

To sum up, osimertinib is an important anti-cancer drug developed and produced by the British company AstraZeneca. With its unique efficacy and relatively mild side effects, it has brought new treatment options to patients with non-small cell lung cancer and has also made important contributions to the global anti-cancer cause.